On Thursday, Gilead Sciences Inc. (NASDAQ:GILD) shares edged lower by 2.3% in the after-hours session despite posting solid fiscal Q3 results. The company announced its most recent quarterly results after markets closed, beating analyst expectations on revenue and earnings. Gilead also issued a better-than-expected FY2021 EPS guidance.
The company posted FQ3 non-GAAP earnings per share of $2.65, beating the consensus analyst estimate of $1.78. On the other hand, its GAAP EPS of $2.05 outperformed the expectation of $1.37, while revenue for the quarter increased by 13.1% from the same quarter in 2020 to $7.42 billion, $1.08 billion ahead of estimates.
The company also raised its earnings guidance to about $7.90-$8.10 from $6.90-$7.25, previously, ahead of the average Street forecast of $7.25.
Is Gilead undervalued?
From an investment perspective, Gilead shares trade at an exciting forward P/E ratio of 9.97, making the stock an attractive option for value investors.
However, with analysts expecting earnings per share to fall by nearly 98% this year before rising at an average annual rate of just 1.32% over the next five years, growth investors could opt for alternatives.
Gilead is substantially underperforming the S&P 500 Index based on its YTD gain of just 12%. Therefore, there is a lot of room left to catch up.
Source – TradingView
Technically, Gilead shares seem to be trading within a descending channel formation in the intraday chart. However, the stock has recently bounced off the trendline support to recover from oversold conditions.
Therefore, with shares still far from reaching overbought conditions, the current rebound could continue, pushing the stock towards the 100-day moving average.
Investors could target profits at about $68.77 or higher at $71.70, while $63.91 and $61.52 are crucial support zones.
Buy the pullback?
In summary, Gilead Sciences shares trade at a compelling forward P/E, making it an ideal opportunity for value investors.
Therefore, given the recent price movement, the post-earnings pullback could be an opportunity to buy.
The post Should you invest in Gilead Sciences after guiding FY2021 earnings above estimates? appeared first on Invezz.
